Bide Pharmatech Co

Bide Pharmatech Co., Ltd. reports **CNY 1,051.27 million in sales** for the nine months ending September 30, 2026, marking a rise from CNY 979.11 million in the same period the prior year. The company’s net income also increases to **CNY 163.94 million**, up from CNY 119.73 million year-over-year. The results reflect growth in revenue and profitability for the biopharmaceutical firm.

Oct 2026MarketScreenerNews article

Bide Pharmatech Co., Ltd. (XSSC:688073) is now included in the S&P Global BMI Index. The company specializes in pharmaceutical technology and innovation. This addition reflects its growing prominence in the biopharmaceutical sector.

Sep 2026MarketScreenerNews article

Bide Pharmatech Co., Ltd. reports **CNY 682.79 million in sales and CNY 682.84 million in revenue** for the half-year ended June 30, 2026. This marks an increase compared to the same period in the prior year, when both figures stood at **CNY 627.53 million**. The company’s financial performance reflects growth in its core operations during the reporting period.

Aug 2026MarketScreenerNews article

Bide Pharmatech Co., Ltd. declares an annual dividend of **CNY 1.16 per share**, set for payment on **June 10, 2026**. The ex-date and record date are both aligned with the dividend payout date, ensuring shareholder eligibility by **June 9, 2026**. The announcement formalizes the company’s distribution policy for its shareholders.

Apr 2026MarketScreenerNews article